preliminari
data
examin
interferon
treatment
sarscov
sever
acut
respiratori
syndromecorona
viru
infect
patient
suggest
therapi
well
toler
therapeut
benefit
report
herein
interferon
potent
vitro
antivir
activ
sarscov
cytopath
effect
protect
cpe
assay
interferon
inhibit
gener
cpe
dosedepend
manner
ic
gml
clinic
achiev
level
furthermor
interferon
also
demonstr
signific
antivir
activ
yield
reduct
plaqu
reduct
assay
vitro
antivir
activ
interferon
sarscov
suggest
continu
evalu
interferon
therapeut
treatment
patient
infect
sarscov
publish
elsevi
bv
sever
acut
respiratori
syndrom
sar
emerg
signific
threat
global
health
etiolog
agent
caus
sar
plusstrand
rna
viru
classifi
coronaviru
sarscov
holm
peiri
et
al
ksiazek
et
al
fouchier
et
al
sar
associ
signific
morbid
mortal
rate
estim
sar
antivir
discoveri
effort
identifi
interferon
potent
inhibitor
sarscov
replic
recent
interferon
use
combin
cortic
steroid
preliminari
pilot
studi
assess
potenti
clinic
benefit
safeti
patient
infect
sarscov
loutfi
et
al
studi
suggest
interferon
safe
suggest
therapeut
benefit
loutfi
et
al
report
describ
vitro
activ
interferon
interferon
cytokin
induc
consequ
viral
infect
pleiotrop
biolog
effect
play
role
modul
innat
adapt
immun
type
interferon
alphabeta
effect
treat
plusstrand
rna
viral
diseas
hepat
c
viru
tong
et
al
human
coronaviru
caus
mild
upper
respiratori
infect
sperber
hayden
other
report
type
interferon
inhibit
sarscov
replic
vitro
cinatl
et
al
hensley
et
al
haagman
et
al
enserink
cinatl
et
al
chen
et
al
moriguchi
sato
stroher
et
al
furthermor
type
interferon
evalu
experiment
infect
nonhuman
primat
enserink
date
interferon
interferon
test
human
trial
loutfi
et
al
examin
vitro
antivir
activ
nonnatur
occur
type
interferon
interferon
infergen
oze
et
al
cellcultur
assay
sarscov
interferon
secondgener
cytokin
engin
contain
frequent
occur
amino
acid
among
nonallel
interferon
alpha
subtyp
blatt
et
al
molecul
uniqu
natur
occur
interferon
cellcultur
model
interferon
demonstr
increas
potenc
compar
natur
occur
type
interferon
blatt
et
al
potent
inhibitor
hepat
c
viru
replic
compar
clinic
trial
natur
occur
type
interferon
tong
et
al
interferon
success
evalu
treat
chronic
hepat
c
viru
infect
suzuki
tango
vitro
cpe
assay
ishitsuka
et
al
imanishi
et
al
interferon
abl
inhibit
sarscov
replic
dosedepend
manner
confluent
cell
plate
treat
gml
pgml
interferon
incub
c
vero
cell
respons
substrat
human
interferon
julkunen
et
al
twentyfour
hour
pretreat
h
h
posttreat
h
posttreat
cell
infect
urbani
strain
sarscov
viru
ksiazek
et
al
multipl
infect
cell
incub
c
addit
h
stain
vital
cell
dye
neutral
red
marker
cell
viabil
imanishi
et
al
stain
cell
wash
extens
phosphatebuff
salin
pb
fix
neutral
buffer
formalin
neutral
red
assay
use
optic
plate
reader
set
nm
optic
densiti
data
collect
inhibitori
concentr
ic
toxic
concentr
tc
determin
use
four
paramet
fit
algorithm
vitro
cpe
assay
interferon
ic
gml
tc
greater
gml
repeat
experi
posttreat
timepoint
time
detect
activ
sarscov
induc
cpe
similar
assay
ribavirin
effect
replic
sarscov
interferon
provid
complet
protect
highest
dose
linear
dose
respons
lower
part
concentr
curv
interferon
also
assay
combin
interferon
gamma
detect
synergi
observ
beyond
activ
interferon
interferon
test
sarscov
plaqu
reduct
assay
confluent
vero
cell
pretreat
supplement
cellcultur
medium
interferon
ngml
h
treat
shamtreat
control
cell
infect
approxim
pfu
one
three
differ
isol
sarscov
urbani
ksiazek
et
al
marra
et
al
h
h
adsorpt
cell
wash
two
time
pb
overlaid
solid
medium
contain
emem
fetal
bovin
serum
agaros
supplement
ngml
interferon
cell
incub
addit
h
stain
solut
neutral
redpb
solut
twentyfour
hour
poststain
fig
neutral
redstain
cell
cultur
plaqu
reduct
assay
compar
sensit
three
isol
sarscov
row
c
show
data
cell
infect
isol
urbani
respect
last
column
show
data
cell
interferon
treat
mock
infect
stain
cell
cultur
photograph
interferon
abl
inhibit
plaqu
format
three
sarscov
isol
fig
column
comparison
sham
treatment
fig
column
differ
plaqu
size
reproduc
among
differ
isol
treatment
interferon
alon
affect
cell
viabil
fig
column
base
neutral
red
uptak
interferon
evalu
yield
reduct
assay
h
time
cours
confluent
vero
cell
pretreat
interferon
ngml
h
infect
three
sarscov
isol
viral
cultur
sampl
h
interv
sampl
store
c
viral
titer
sampl
assay
plaqu
assay
cell
describ
titer
plot
line
graph
fig
interferon
block
viral
product
h
postinfec
fig
line
graph
yieldreduct
experi
pfuml
plot
xaxi
time
plot
yaxi
open
symbol
treat
data
close
symbol
shamtreat
data
follow
shape
repres
differ
sarscov
isol
diamond
repres
squar
triangl
urbani
tion
comparison
mocktreat
cell
h
interferon
reduc
replic
sarscov
isol
log
compar
replic
mocktreat
cell
urbani
isol
remain
complet
inhibit
seventytwo
hour
postinfect
treat
cultur
infect
reach
peak
titer
pfuml
repres
reduct
compar
untreat
urbani
isol
remain
complet
inhibit
h
time
point
urbani
isol
achiev
peak
viral
titer
log
viru
log
less
titer
untreat
control
cell
cultur
stain
crystal
violet
photograph
fig
infect
cell
treat
interferon
appear
protect
cpe
base
crystal
violet
stain
stain
pattern
interferon
infect
cell
fig
column
similar
stain
pattern
uninfect
cell
fig
column
shamtreat
infect
cell
fig
column
extens
cpe
compar
treat
mockinfect
fig
column
detect
cpe
macroscop
microscop
result
surpris
compar
viral
titer
data
peak
titer
pfuml
urbani
isol
peak
titer
pfuml
cell
free
cell
cultur
media
sampl
fig
interferon
appear
protect
cell
cpe
despit
limit
viral
replic
therefor
given
proven
efficaci
safeti
interferon
treatment
chronic
hepat
c
flaviviru
infect
effect
anticoronaviru
dose
potenti
achiev
patient
suzuki
tango
potent
abil
interferon
protect
cell
virusinduc
cpe
suggest
compound
inhibit
viral
replic
fig
substanti
yield
reduct
plaqu
reduct
assay
suggest
interferon
effect
antivir
multipl
isol
sarscov
yieldreduct
experi
model
reduct
delay
peak
titer
may
allow
infect
individu
time
effect
contain
viru
interest
despit
viral
replic
late
time
infect
yieldreduct
assay
fig
detect
cpe
fig
potenti
interferon
may
function
antivir
therapeut
treat
sar
patient
expos
individu
loutfi
et
al
interferon
like
induc
antivir
state
cell
result
cellular
environ
favor
viral
replic
interferon
induc
number
cellular
antivir
factor
blatt
et
al
howev
attempt
treat
infect
cell
postinfect
interferon
show
activ
cpe
base
assay
yield
reduct
experi
data
shown
suggest
interferon
mayb
directli
block
viral
replic
cell
alreadi
infect
rather
interferon
may
suppress
viral
spread
uninfect
cell
make
cell
refractori
viral
infect
levi
garciasastr
basler
garciasastr
part
normal
cellular
respons
type
interferon
treatment
may
also
suggest
sarscov
contain
viral
gene
product
function
interferon
antagonist
like
rna
virus
levi
garciasastr
basler
garciasastr
investig
vitro
mechan
interferon
need
result
suggest
interferon
vitro
abil
inhibit
sarscov
replic
interferon
potenti
therapeut
agent
patient
acut
ill
sar
await
investig
